Degenerative Disc Disease Treatment Market Size, Share, Opportunities And Trends By Type (Drugs, Therapy), By End-User (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Others), And By Geography - Forecasts From 2023 To 2028

  • Published : Mar 2023
  • Report Code : KSI061614515
  • Pages : 138

Degenerative disc disease is an aging-related disorder of the discs between the vertebrae that results in cushioning loss, fragmentation, and herniation. It is caused by the breakdown of the intervertebral discs that act as shock absorbers between the vertebrae. As a result, patients experience back pain, stiffness, and decreased mobility. As the world's population ages and degenerative disc disease becomes more common, the treatment market is anticipated to expand dramatically during the subsequent years. DDD can be treated with a variety of methods, such as drugs, physical therapy, and surgery. Muscle relaxants, NSAIDs, and opioid analgesics are a few examples of medications that can aid with pain and inflammation management. Strength, flexibility, and mobility can all be enhanced with physical therapy.

Regenerative medicine methods for treating DDD have drawn more attention in recent years. Two of these methods under study are platelet-rich plasma (PRP) therapy and stem cell therapy. These treatments involve regenerating damaged tissue and encouraging recovery using the patient's own cells. While there is still much to understand in this domain, regenerative medicine techniques show promise for developing fresh, ground-breaking treatments for DDD. As more cutting-edge and novel treatments become accessible, the degenerative disc disease treatments market is anticipated to expand. There will be a rising need for efficient and economical treatments for DDD as the population ages and the prevalence of the ailment rises.

The degenerative disc disease treatment market is driven by the rising cases and awareness regarding DDD and advanced treatment options.

DDD is becoming more prevalent as the population advances. According to reports from the World Health Organization (WHO) there will be 2 billion people in the world who are 60 years of age or older by 2050, which can increase the demand for DDD treatments. Degenerative disc disease is a prevalent disorder that affects 30% of individuals aged 30 to 50 and 60% of people over 50, according to the US National Institute of Neurological Disorders and Stroke. The demand for DDD therapies is anticipated to be driven by the growing knowledge of the symptoms and available DDD remedies. This is a result of increased public education initiatives and campaigns by governmental and non-governmental groups to increase understanding of DDD and the health dangers linked to it. According to the US Centers for Disease Control and Prevention, chronic pain, including back pain brought on by degenerative disc degeneration, is a serious public health issue and a major contributor to disability in the country.

The degenerative disc disease treatment market is anticipated to expand as a result of the development of novel technologies and therapeutic modalities including stem cell therapy and PRP therapy. These novel therapies have the potential to offer DDD patients longer-lasting and more potent therapies. According to papers published by the US National Center for Biotechnology Information, preclinical and clinical trials on stem cell therapy and PRP therapy for degenerative disc degeneration have yielded encouraging results.

Key developments.

  • In February 2020, DiscGenics, Inc., a diagnostic phase biopharmaceutical firm centered on establishing cell-based regenerative therapies that reduce pain and restore function in patients, announced that the U.S. Food and Drug Administration (FDA) had designated Injectable Disc Cell Therapy (IDCT or rebonuputemcel), an injectable, allogeneic discogenic progenitor cell therapy, as a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of symptoms of degenerative diseases of the spine (DDD). The RMAT classification is based on promising two-year clinical results from DiscGenics' first-in-human trial using IDCT. The study showed that in individuals with lumbar DDD, IDCT has the ability to increase disc volume without risk and to quickly and permanently reduce low back pain, function, quality of life, and opiate use for up to two years after injection.

Asia Pacific and North America accounted for major shares of the Degenerative disc disease treatment market.

Based on geography, the Degenerative disc disease treatment market is segmented into North America, South America, Europe, the Middle East and Africa and Asia Pacific. Given the high prevalence of DDD and rising healthcare costs in the region, North America is anticipated to hold significant portions of the degenerative disc disease treatment market. The existence of major market players and the expanding acceptance of novel and cutting-edge treatments are additional factors anticipated to fuel market expansion. Asia-Pacific is anticipated to have the a substantial growth rate in the degenerative disc disease treatment market due to the rising prevalence of DDD, rising healthcare costs, and more awareness of the ailments. A sizable patient base and the emergence of cutting-edge healthcare infrastructure are further factors anticipated to fuel market expansion. Degenerative disc disease is very common throughout Asia, with a prevalence rate of up to 70% in some nations, according to a report by the International Association for the Study of the Lumbar Spine. 

Key Market Segments

  • By Type
    • Drugs
      • NSAIDs
      • Pain relief medication
      • Steroids
      • Muscle relaxers
    • Therapy
  • By End-User
    • Hospitals
    • Ambulatory Surgical Centers
    • Orthopedic Clinics
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East And Africa
      • Saudi Arabia
      • Israel
      • UAE
      • Other
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Vietnam
      • Indonesia
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Drugs

5.2.1. NSAIDs

5.2.2. Pain relief medication

5.2.3. Steroids 

5.2.4. Muscle relaxers

5.3. Therapy


6.1. Introduction

6.2. Hospitals

6.3. Ambulatory Surgical Centers

6.4. Orthopedic Clinics

6.5. Others


7.1. Introduction

7.2. North America

7.2.1. USA

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Others

7.5. Middle East And Africa

7.5.1. Saudi Arabia

7.5.2. Israel

7.5.3. UAE

7.5.4. Other

7.6. Asia Pacific

7.6.1. China

7.6.2. Japan

7.6.3. India

7.6.4. South Korea

7.6.5. Australia

7.6.6. Vietnam

7.6.7. Indonesia

7.6.8. Others


8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisition, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix


9.1. QI Lifecare Pvt. Ltd

9.2. Medtronic

9.3. DiscGenics

9.4. NuVasive, Inc.

9.5. Bayer

9.6. Haleon Group

9.7. Johnson & Johnson

9.8. Polar Products

QI Lifecare Pvt. Ltd



NuVasive, Inc.


Haleon Group

Johnson & Johnson

Polar Products